Table 4 Open in new tab Changes at...

Characteristic

Targeted therapy (N = 102)

Conventional therapy (N = 105)

Δ Targeted therapy (baseline vs. 5 years) %

Δ Conventional therapy (baseline vs. 5 years) %

P-value targeted therapy baseline vs. 5 years

P-value conventional treatment baseline vs. 5 years

P-value Δ targeted vs. conventional

Systolic blood pressure (mmHg)

Baseline

130.9 ± 15.3

128.3 ± 14.4

−1.80%

4.68%

0.062

0.008

0.003

5 years

126.4 ± 14.9

133.3 ± 16.3

Diastolic blood pressure (mmHg)

Baseline

83.4 ± 10.5

82.1 ± 9.5

−5.98%

−2.30%

<0.001

0.026

0.138

5 years

77.0 ± 9.7

79.5 ± 11.1

Body mass index (kg/m²)

Baseline

28.5 (25.8–30.9)

28.1 (25.6–30.7)

0.62%

1.37%

0.395

0.023

0.292

5 years

28.4 (25.6–31.4)

28.4 (25.8–31.4)

NT-ProBNP (ng/L)

Baseline

1071 (687–1537)

987 (683–1548)

−34.94%

−23.99%

<0.001

0.428

5 years

475 (118–828)

512 (135–1038)

Total cholesterol (mmol/L)

Baseline

5.0 (4.2–5.7)

4.0 (4.1–5.8)

−14.56%

−3.13%

<0.001

0.015

0.003

5 years

4.0 (3.5–4.8)

4.7 (3.9–5.4)

LDL cholesterol (mmol/L)

Baseline

3.0 (2.4–3.8)

2.9 (2.5–3.8)

−16.50%

−5.59%

<0.001

0.002

0.017

5 years

2.1 (1.7–2.7)

2.7 (2.1–3.6)

Left atrial volume indexed (mL/m²)

Baseline

39 (31–48)

38 (31–48)

9.50%

11.91%

0.925

0.218

0.542

5 years

39 (32–48)

40 (30–49)

LVEF

Baseline

54 (43–59)

52 (43–60)

11.25%

13.12%

0.001

<0.001

0.831

5 years

55 (50–60)

55 (51–60)

Urine sodium (mmol/24 h)

Baseline

161 (118–210)

166 (122–217)

−10.80%

−11.64%

0.118

0.125

0.691

5 years

162 (102–196)

159 (125–193)

Exercise test (W)

Baseline

137 (108 –165)

134 (100–160)

0.26%

−3.82%

0.128

0.005

0.851

5 years

139 (99–173)

126 (90–162)

Table 4

Open in new tab

Changes at 5-year follow-up

Characteristic	Targeted therapy (N = 102)	Conventional therapy (N = 105)	Δ Targeted therapy (baseline vs. 5 years) %	Δ Conventional therapy (baseline vs. 5 years) %	P-value targeted therapy baseline vs. 5 years	P-value conventional treatment baseline vs. 5 years	P-value Δ targeted vs. conventional
Systolic blood pressure (mmHg)
Baseline	130.9 ± 15.3	128.3 ± 14.4	−1.80%	4.68%	0.062	0.008	0.003
5 years	126.4 ± 14.9	133.3 ± 16.3
Diastolic blood pressure (mmHg)
Baseline	83.4 ± 10.5	82.1 ± 9.5	−5.98%	−2.30%	<0.001	0.026	0.138
5 years	77.0 ± 9.7	79.5 ± 11.1
Body mass index (kg/m²)
Baseline	28.5 (25.8–30.9)	28.1 (25.6–30.7)	0.62%	1.37%	0.395	0.023	0.292
5 years	28.4 (25.6–31.4)	28.4 (25.8–31.4)
NT-ProBNP (ng/L)
Baseline	1071 (687–1537)	987 (683–1548)	−34.94%	−23.99%	<0.001	<0.001	0.428
5 years	475 (118–828)	512 (135–1038)
Total cholesterol (mmol/L)
Baseline	5.0 (4.2–5.7)	4.0 (4.1–5.8)	−14.56%	−3.13%	<0.001	0.015	0.003
5 years	4.0 (3.5–4.8)	4.7 (3.9–5.4)
LDL cholesterol (mmol/L)
Baseline	3.0 (2.4–3.8)	2.9 (2.5–3.8)	−16.50%	−5.59%	<0.001	0.002	0.017
5 years	2.1 (1.7–2.7)	2.7 (2.1–3.6)
Left atrial volume indexed (mL/m²)
Baseline	39 (31–48)	38 (31–48)	9.50%	11.91%	0.925	0.218	0.542
5 years	39 (32–48)	40 (30–49)
LVEF
Baseline	54 (43–59)	52 (43–60)	11.25%	13.12%	0.001	<0.001	0.831
5 years	55 (50–60)	55 (51–60)
Urine sodium (mmol/24 h)
Baseline	161 (118–210)	166 (122–217)	−10.80%	−11.64%	0.118	0.125	0.691
5 years	162 (102–196)	159 (125–193)
Exercise test (W)
Baseline	137 (108 –165)	134 (100–160)	0.26%	−3.82%	0.128	0.005	0.851
5 years	139 (99–173)	126 (90–162)

Characteristic	Targeted therapy (N = 102)	Conventional therapy (N = 105)	Δ Targeted therapy (baseline vs. 5 years) %	Δ Conventional therapy (baseline vs. 5 years) %	P-value targeted therapy baseline vs. 5 years	P-value conventional treatment baseline vs. 5 years	P-value Δ targeted vs. conventional
Systolic blood pressure (mmHg)
Baseline	130.9 ± 15.3	128.3 ± 14.4	−1.80%	4.68%	0.062	0.008	0.003
5 years	126.4 ± 14.9	133.3 ± 16.3
Diastolic blood pressure (mmHg)
Baseline	83.4 ± 10.5	82.1 ± 9.5	−5.98%	−2.30%	<0.001	0.026	0.138
5 years	77.0 ± 9.7	79.5 ± 11.1
Body mass index (kg/m²)
Baseline	28.5 (25.8–30.9)	28.1 (25.6–30.7)	0.62%	1.37%	0.395	0.023	0.292
5 years	28.4 (25.6–31.4)	28.4 (25.8–31.4)
NT-ProBNP (ng/L)
Baseline	1071 (687–1537)	987 (683–1548)	−34.94%	−23.99%	<0.001	<0.001	0.428
5 years	475 (118–828)	512 (135–1038)
Total cholesterol (mmol/L)
Baseline	5.0 (4.2–5.7)	4.0 (4.1–5.8)	−14.56%	−3.13%	<0.001	0.015	0.003
5 years	4.0 (3.5–4.8)	4.7 (3.9–5.4)
LDL cholesterol (mmol/L)
Baseline	3.0 (2.4–3.8)	2.9 (2.5–3.8)	−16.50%	−5.59%	<0.001	0.002	0.017
5 years	2.1 (1.7–2.7)	2.7 (2.1–3.6)
Left atrial volume indexed (mL/m²)
Baseline	39 (31–48)	38 (31–48)	9.50%	11.91%	0.925	0.218	0.542
5 years	39 (32–48)	40 (30–49)
LVEF
Baseline	54 (43–59)	52 (43–60)	11.25%	13.12%	0.001	<0.001	0.831
5 years	55 (50–60)	55 (51–60)
Urine sodium (mmol/24 h)
Baseline	161 (118–210)	166 (122–217)	−10.80%	−11.64%	0.118	0.125	0.691
5 years	162 (102–196)	159 (125–193)
Exercise test (W)
Baseline	137 (108 –165)	134 (100–160)	0.26%	−3.82%	0.128	0.005	0.851
5 years	139 (99–173)	126 (90–162)

Data are presented as mean (SD), number of patients (%), or median (IQR). Delta represents mean change at 5-year follow-up in percentages.

LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide.

This Feature Is Available To Subscribers Only